SciBase launches SEK 58 million rights issue for expansion
Shareholders and investors commit to cover the full amount. Proceeds finance US market commercialisation efforts.
See the latest news and media coverage for SciBase. We track all announcements, press releases, and industry mentions in real time, all in one place.
Dermatology medical technology company
scibase.comLast updated
In short: SciBase reported strong sales growth, submitted a 510(k) to the FDA for skin cancer, and saw CEO Pia Renaudin announce her departure.
Shareholders and investors commit to cover the full amount. Proceeds finance US market commercialisation efforts.
CEO Pia Renaudin steps down, board initiates recruitment for successor, strategy unchanged.
The submission seeks to clear Nevisense for keratinocyte skin cancer, the most common cancer in the US, with over 5.4 million annual cases.
Study published in Allergy found higher neonatal EIS scores linked to atopic dermatitis development in first year.
The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") is publishing an information document in connection with the rights issue ...
Scibase has decided to carry out a new share issue of approximately 57.5 million Swedish kronor before deduction for transaction costs, with pre-emptive rights for...
/PRNewswire/ -- January 1 - June 30, 2026 The second quarter in figures Net sales were TSEK 15,308 (8,791), +74%, cleared for currency effects +84...
Medtech company Scibase reports an operating result of minus 28.8 million kronor (minus 22.4) for the second quarter.
Track SciBase and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.